Sophiris Bio (NASDAQ:SPHS) Covered By Yet Another Research Firm

May 18, 2018 - By Karen Cook

Sophiris Bio, Inc. (NASDAQ:SPHS) Logo

Investors sentiment increased to 2.8 in Q4 2017. Its up 2.16, from 0.64 in 2017Q3. It is positive, as 2 investors sold Sophiris Bio, Inc. shares while 3 reduced holdings. 8 funds opened positions while 6 raised stakes. 1.87 million shares or 14.89% more from 1.63 million shares in 2017Q3 were reported.

Wells Fargo & Communication Mn has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). 55,907 are held by Sabby Management Ltd. Bancshares Of America Corp De stated it has 0% of its portfolio in Sophiris Bio, Inc. (NASDAQ:SPHS). Virtu Financial Lc accumulated 169,790 shares. Geode Cap Mngmt Limited Liability Corporation invested 0% of its portfolio in Sophiris Bio, Inc. (NASDAQ:SPHS). Jpmorgan Chase Com, New York-based fund reported 23,401 shares. Natl Bank Of Montreal Can owns 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 11,210 shares. Macquarie Grp Limited has 0% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 3,700 shares. Lpl Fincl Llc stated it has 10,000 shares or 0% of all its holdings. 784,834 are held by Vanguard Gru Inc. Millennium Mngmt Limited Company accumulated 199,705 shares. Edge Wealth Ltd holds 0% of its portfolio in Sophiris Bio, Inc. (NASDAQ:SPHS) for 2,000 shares. 23,656 were accumulated by Bankshares Of Mellon Corporation. B T Cap Mgmt Dba Alpha Cap Mgmt owns 10,128 shares or 0.01% of their US portfolio. Architects Inc accumulated 800 shares.

Why Has Piper Jaffray Given Sophiris Bio (NASDAQ:SPHS) a $7.0000 Price Target

Investment firm Piper Jaffray has today began coverage on Sophiris Bio (NASDAQ:SPHS) shares, with a “Buy” rating, while giving it the price target at $7.0000.

The stock decreased 4.27% or $0.15 during the last trading session, reaching $3.36. About 599,584 shares traded or 126.56% up from the average. Sophiris Bio, Inc. (NASDAQ:SPHS) has declined 26.06% since May 18, 2017 and is downtrending. It has underperformed by 37.61% the S&P500.

Analysts await Sophiris Bio, Inc. (NASDAQ:SPHS) to report earnings on May, 21. They expect $-0.12 EPS, down 33.33 % or $0.03 from last year’s $-0.09 per share. After $-0.11 actual EPS reported by Sophiris Bio, Inc. for the previous quarter, Wall Street now forecasts 9.09 % negative EPS growth.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $93.88 million. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

More important recent Sophiris Bio, Inc. (NASDAQ:SPHS) news were published by: which released: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” on May 15, 2018, also published article titled: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings”, published: “Premarket analyst action – healthcare” on May 18, 2018. More interesting news about Sophiris Bio, Inc. (NASDAQ:SPHS) was released by: and their article: “45 Biggest Movers From Yesterday” with publication date: May 16, 2018.

Sophiris Bio, Inc. (NASDAQ:SPHS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.